Ligand Pharmaceuticals

Ligand Pharmaceuticals is a publicly traded biopharmaceutical company that operates a royalty-driven business model around licensed drug programs, captive technology platforms, and partnered pipelines. It is not a venture fund in the conventional sense, and founders should not treat it as a source of priced equity rounds. Where Ligand can be relevant is as a strategic partner for biotech and small-molecule founders who are willing to trade upside for non-dilutive capital, royalties on milestones, or access to formulation, antibody discovery, and partnered-program infrastructure. The most relevant founder is running a preclinical or clinical-stage drug company with a defensible asset that needs capital and platform support but not classical VC scaling. Digital health, AI software, services businesses, devices, and most diagnostics fall outside the relevant scope. Geography is US-anchored but the deal engagement is global wherever the underlying asset has commercial promise. Entry runs through Ligand’s business development team rather than a partner inbox; founders should approach with a one-page asset summary, IP status, and a clear ask, then expect a structured diligence process more akin to a pharma BD conversation than a venture pitch. Treat any engagement as a partnership negotiation with legal complexity, and retain counsel experienced with royalty financings before signing terms. For most physician AI founders, Ligand will not be the right name on the cap table.